Development of Novel Therapeutics for Schizophrenia Treatment Based on a Selective Positive Allosteric Modulation of α1-Containing GABAARs—In Silico Approach

Development of Novel Therapeutics for Schizophrenia Treatment Based on a Selective Positive Allosteric Modulation of α1-Containing GABAARs—In Silico Approach

For the development of atypical antipsychotics, the selective positive allosteric modulation of the ionotropic GABAA receptor (GABAAR) has emerged as a promising approach. In the presented research, two unrelated methods were used for the development of QSAR models for selective positive allosteric...

Full description

Bibliographic Details
Main Authors: Vladimir Đorđević, Milan Petković, Jelena Živković, Goran M. Nikolić, Aleksandar M. Veselinović
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Current Issues in Molecular Biology
Subjects:
GABAA receptor
schizophrenia
QSAR
molecular modeling
drug design
Online Access:https://www.mdpi.com/1467-3045/44/8/234

Similar Items

Similar Items